Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks.com headshot

Novavax Begins Clinical Study for Coronavirus Vaccine

by Zacks.com

Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.

Ritujay Ghosh headshot

Coronavirus Vaccine Development Gathers Steam: 4 Winners

by Ritujay Ghosh

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

Sanghamitra Saha headshot

Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

by Sanghamitra Saha

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

Ritujay Ghosh headshot

Coronavirus Vaccine Race Pushes Up Pharma Giants' Production

by Ritujay Ghosh

Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.

Zacks Equity Research

Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (MRNA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Company News for May 21, 2020

by Zacks Equity Research

Companies In The News Are: MRNA, FB, CLX, RCL.

Sweta Jaiswal, FRM headshot

Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

by Sweta Jaiswal, FRM

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

Zacks Equity Research

Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More

by Zacks Equity Research

The biotech sector remains in focus with pipeline updates on coronavirus treatments.

Zacks Equity Research

Stock Market News for May 20, 2020

by Zacks Equity Research

U.S. stock markets closed lower on Tuesday following the news that a potential vaccine candidate for the treatment of the coronavirus may not be effective.

Zacks Equity Research

Moderna Declines on Skepticism on Coronavirus Vaccine Data

by Zacks Equity Research

Moderna (MRNA) shares decline following a report raising questions on clinical data announced earlier this week related to its coronavirus vaccine.